Sangamo bulks up in cell therapy with TxCell acquisition
Sangamo has agreed a €72m deal to take control of French biotech TxCell, eyeing a regulatory T cell (Treg) platform that it says would accelerate its plans to enter the cell therapy market.
Sangamo’s zinc finger nuclease (ZFN) gene-editing technology is already being used to create chimeric antigen receptor T cell (CAR-T) cancer therapies under a $3b-plus deal with Gilead’s Kite unit, signed earlier this year, and it also has an early-stage programmes in stem cell therapies for blood diseases and off-the-shelf (allogeneic) CAR-Ts for cancer.
By acquiring TxCell, Sangamo thinks it will be able to start trials of cell-based immunotherapies as early as next year, headed by TxCell’s TX200 candidate to prevent graft rejection in solid organ transplant patients and with follow-up projects in other autoimmune diseases and inflammatory such as Crohn’s disease and multiple sclerosis. It plans to a start a phase I/II trial in Europe before the end of 2019.
Read more: http://www.pmlive.com/pharma_news/sangamo_bulks_up_in_cell_therapy_with_txcell_acquisition_1245315
Sangamo’s zinc finger nuclease (ZFN) gene-editing technology is already being used to create chimeric antigen receptor T cell (CAR-T) cancer therapies under a $3b-plus deal with Gilead’s Kite unit, signed earlier this year, and it also has an early-stage programmes in stem cell therapies for blood diseases and off-the-shelf (allogeneic) CAR-Ts for cancer.
By acquiring TxCell, Sangamo thinks it will be able to start trials of cell-based immunotherapies as early as next year, headed by TxCell’s TX200 candidate to prevent graft rejection in solid organ transplant patients and with follow-up projects in other autoimmune diseases and inflammatory such as Crohn’s disease and multiple sclerosis. It plans to a start a phase I/II trial in Europe before the end of 2019.
Read more: http://www.pmlive.com/pharma_news/sangamo_bulks_up_in_cell_therapy_with_txcell_acquisition_1245315